BlackRock, Inc. acquired 2.99 million shares of Sinopharm (H shares) by way of taking a security interest in shares on October 2, 2026. The transaction was an off-exchange acquisition with non-cash assets as consideration, not matched on the SEHK open market and therefore not a direct secondary-market dealing.
Prior to the acquisition, BlackRock, Inc.'s long position in Sinopharm was 118.40 million shares, representing 8.82%; following the acquisition, the holding changed to 121.39 million shares, with the long position ratio rising to 9.05%.